DOT Spectacle Lenses for Nearsightedness
(ASH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to compare two types of glasses to assess their impact on the eyes' ability to focus on nearby objects. Participants will wear either DOT spectacle lenses or regular glasses to measure differences in focus adjustment. The trial seeks young individuals with normal vision (neither too nearsighted nor farsighted) who haven't undergone recent eye treatments. Those without treatments for myopia in the past year and without conditions like lazy eye may qualify. As an unphased trial, this study provides a unique opportunity to contribute to understanding vision correction in young people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are using any medications that might affect the study results, you may not be eligible to participate.
What prior data suggests that DOT spectacle lenses are safe for nearsightedness?
Research has shown that DOT spectacle lenses are safe for use. A 12-month study found that these lenses not only are safe but also help slow the progression of nearsightedness. Another study found no serious eye problems in children who wore these lenses for 18 months. These findings suggest that DOT spectacle lenses are well-tolerated and have a strong safety record.12345
Why are researchers excited about this trial?
Researchers are excited about DOT Spectacle Lenses for nearsightedness because they offer a new approach to correcting vision. Unlike traditional corrective lenses that simply refocus light on the retina, DOT Spectacle Lenses use a special dot pattern to potentially slow down the progression of nearsightedness. This innovative design could not only correct vision but also address the underlying progression of the condition, which is something standard lenses do not do. This dual action is what makes DOT Spectacle Lenses a promising option for those looking to manage their nearsightedness more effectively.
What evidence suggests that this trial's treatments could be effective for nearsightedness?
Research has shown that DOT spectacle lenses, one of the treatments in this trial, effectively control nearsightedness (myopia) in children. Studies have found that these lenses significantly slow the progression of myopia over time. For example, more than half of the children who wore DOT lenses did not experience significant worsening of their nearsightedness over an 18-month period. Additionally, the lenses reduced myopia progression over 36 months in children as young as six years old. These findings suggest that DOT lenses can be a powerful tool for managing myopia in young patients. Participants in this trial will receive either DOT spectacle lenses or control spectacles to evaluate their effectiveness.13467
Are You a Good Fit for This Trial?
This trial is for children and teenagers aged 6-18 who can read or understand consent documents, with nearsightedness within specific limits (+1.00D to -1.00D). They must be able to follow instructions and have no history of myopia treatment in the past year, amblyopia, binocular vision disorders, active eye diseases/infections, or systemic conditions like diabetes that could affect results.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are fitted with either DOT spectacle lenses or control spectacles to measure the lag of accommodation
Follow-up
Participants are monitored for any immediate effects post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- Control Spectacles
- DOT Spectacle Lenses
Find a Clinic Near You
Who Is Running the Clinical Trial?
SightGlass Vision, Inc.
Lead Sponsor
University of Waterloo
Collaborator